ASBP
Aspire BiopharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASBP
Aspire Biopharma Holdings, Inc.
A biotechnology company focused on developing innovative drug delivery mechanisms
188 Grand Street Unit #195, New York, NY 10013
--
Aspire Biopharma Holdings, Inc., was formed on February 9, 2021, and is a Delaware corporation. The company is an early-stage biopharmaceutical company in the business of developing and marketing disruptive technologies for new delivery mechanisms, initially for "no harm" drugs. To date, Aspire has developed and acquired disruptive technologies, which are new soluble formulations designed to address issues such as emergencies, drug efficacy, dose management and response time. Aspire's focus is to develop any number of soluble, PH-neutral, quick-acting powder or granular forms that allow rapid sublingual absorption of the product.
Company Financials
EPS
ASBP has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected 0, missing expectations. The chart below visualizes how ASBP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ASBP has released its 2025 Q3 earnings report, with revenue of 1.94K, reflecting a YoY change of NaN%, and net profit of -1.85M, showing a YoY change of -755.64%. The Sankey diagram below clearly presents ASBP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
